A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders
Au H, Zheng Y, Le G, Wong S, Phan L, Teopiz K, Kwan A, Rhee T, Rosenblat J, Ho R, McIntyre R. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders. Journal Of Affective Disorders 2024, 370: 321-327. PMID: 39515485, DOI: 10.1016/j.jad.2024.11.019.Peer-Reviewed Original ResearchDorsal default mode networkFunctional connectivityMental disordersAssociated with decreased functional connectivityAssociated with increased functional connectivityRight frontal-parietal networkLateral orbitofrontal cortexFrontal-parietal networkDefault mode networkIncreased functional connectivityBrain functional connectivityBrain functional activityGlucagon-like peptide-1Orbitofrontal cortexPsychopathological domainsSalience networkVisuospatial networkMode networkParietal networkPsychiatric disordersBrain circuitsNeural circuitsGLP-1RAsGlucagon-like peptide-1 receptor activationReceptor agonistsElectroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
Le G, Wong S, Lu A, Vasudeva S, Gill H, Badulescu S, Portelles D, Zheng Y, Teopiz K, Meshkat S, Kwan A, Ho R, Rhee T, Rosenblat J, Mansur R, McIntyre R. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review. Journal Of Affective Disorders 2024, 368: 798-819. PMID: 39299586, DOI: 10.1016/j.jad.2024.09.081.Peer-Reviewed Original ResearchReuptake inhibitorsDepressive disorderPathophysiology of depressive disordersSystematic reviewAssociated with SSRIsClass of SSRIsNorepinephrine reuptake inhibitorsDoses of antidepressantsSerotonin reuptake inhibitorsFDA-approved agentsVortioxetine treatmentBlock reuptakeAntidepressant exposureSerotonin transporterSNRISSRIsVortioxetineDatabase inceptionConverging evidenceFunctional connectivitySerotoninNeural activityElectroencephalography signaturesStudy investigated changesInhibitors